NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic options to promote growth of its Quell^® neuromodulation and DPNCheck^® neurodiagnostic businesses and to maximize shareholder value.

Read more at globenewswire.com